Fig. 6: 89ZED88082A uptake in relation to CAR T-cell therapy outcomes. | Nature Communications

Fig. 6: 89ZED88082A uptake in relation to CAR T-cell therapy outcomes.

From: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study

Fig. 6

a Time to progression and overall survival curves (in months) according to pre-CART geometric mean SUVpeak lower and higher than the median (3.9). P-values were derived using the log-rank test. b Violin plot representing the relationship of pre-CART SUVpeak in patients achieving complete response or not (CR: 145 lesions in 16 patients, no CR: 69 lesions in five patients). c Violin plot representing the relationship of pre-CART tumor SUVpeak in patients with CRS grade ≥2 (150 lesions in 11 patients) and patients with CRS grade <2 (64 lesions in 10 patients). d, e Violin plot representing the relationship in pre-CART (d) and post-CART (e) brain SUVmean between patients with ICANS grade ≥2 (n = 12) and patients with ICANS grade <2 (n = 9). b–e Black vertical lines are the geometric mean 95% CI; white dots are the geometric means. P-values were obtained from linear mixed models that accounted for clustering within patients, using a likelihood ratio test with maximum likelihood. Adj., volume-adjusted. CART, chimeric antigen receptor T-cell therapy. CR, complete remission. CRS, cytokine release syndrome. geom, geometric. ICANS, immune effector cell-associated neurotoxicity syndrome. Source data are provided as a Source Data file.

Back to article page